Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe